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ABSTRACT 
 
The introduction of computer software which enables assessment of various metabolic parameters has added value to the 
imaging, diagnosis and prognosis of oesophageal carcinoma (OC). Positron emission tomography/Computed tomography     
(PET/CT) is an imaging modality used for monitoring and follow-up of patients with flourodeoxyglucose (FDG) avid 
lesions in OC. The association of HIV with OC remains controversial, however in Kwa-Zulu Natal (KZN), where the 
incidence of this infection is high, the role of PET/CT in predicting the prognostic outcome of OC is important and may 
provide further information that may alter treatment.  
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ost of the oesophageal carcinoma (OC) falls into 
2 histological types that occur most frequently, 
these are squamous cell carcinoma and 
adenocarcinoma. Squamous cell carcinoma originates from 
the epithelium lining the oesophagus, while the malignant 
epithelial cells in adenocarcinoma are arranged in a 
glandular formation. In the past, squamous cell carcinoma 
occurred more frequently but, over the past couple of 
decades, an increase in adenocarcinoma of the oesophagus 
has been noted [1]. A patient’s ethnicity plays an important 
role in the development of OC, which is illustrated by the 
drastic difference between the incidences of OC in Black 
and White ethnic groups [2]. OC in Black South Africans 
was very rare until the last couple of decades [3].  
 According to a case-control study performed in 
Soweto, South Africa, involving 200 OC patients and 391 
hospital controls, pipe tobacco and the consumption of 
traditional beer were identified as risk factors for rural 
Black populations [4]. Patients who drink beer fermented 
from infected maize have also been found to be more 
likely to develop OC [5].  
 There has been an overwhelming shift in African 
People's health-seeking behavior with people opting for 
modern medicine such that, they prefer consulting a 
physician to a traditional healer. Therefore, the continuous 
increase in the OC incidence can be partly attributed to the 
improved diagnosis over the cumulative increased number 
of clients and patients consulting physicians in the region 
[6]. The diagnosis of OC is often made late, when 
screening is no longer beneficial. In countries with a high 
incidence of OC, such as China, population screening 
programmes may be employed. In Western countries, 
however, where the incidence is usually lower, these 
screening programmes are not always applied [7].  
 Screening for asymptomatic diseases, such as OC, in 
its early stages can reduce the burden of morbidity and 
mortality in all population groups. Few data are available 
on national screening rates in South Africa and how the 
data vary across the provinces [8]. The availability of data 
on screening and surveillance protocols of squamous cell 
carcinoma of the oesophagus in Kwa-Zulu Natal (KZN) is 
also limited.  
M 
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 In patients with early-stage malignancy at presentation, 
oesophagectomy is the treatment of choice and is 
potentially curative. Unfortunately, most patients have 
locally advanced disease at presentation, and 20%–30% 
have distant metastases. In patients with locally advanced 
disease without distant metastases, oesophagectomy is a 
potential treatment option after neoadjuvant chemotherapy 
and radiation therapy in those who do not develop distant 
metastases during therapy [9-12]. The main reason for the 
poor prognosis is that OC is largely asymptomatic in its 
early stages. Thus, most cases are diagnosed when the 
disease has become either locally advanced, with disease 
spreading to local draining lymph nodes, or distantly 
metastatic [13].  
 In all patients with potentially resectable disease, 
accurate staging at initial presentation and assessment of 
therapeutic response after neoadjuvant therapy are 
important in regard to optimal management. 
DIAGNOSTIC EVOLUTION  
Staging methods include upper endoscopic 
gastroduodenoscopy (EGD), endoscopic ultrasonography 
(EUS), and computed tomography (CT) of the thorax and 
abdomen. Metabolic assessment is difficult with 
conventional methods. Positron emission tomography 
(PET) is a non-invasive molecular imaging tool that 
provides tomographic images and quantitative parameters 
of perfusion, cell viability, proliferation and/or metabolic 
activity of tissues. These images result from the use of 
different substances of biological interest (sugars, amino 
acids, metabolic precursors, hormones) labelled with PET 
radionuclides). Fusion of the aforementioned important 
functional information with the morphological detail 
provided by CT as PET/CT provides clinicians with a 
sensitive and accurate one-step whole-body diagnostic and 
prognostic tool, which directs and changes patient 
management. 
 According to Nuclear medicine guidelines in South 
Africa, fluoro-2-deoxyglucose (FDG) PET/CT imaging is 
not recommended in screening and diagnosis of OC. It is 
recommended in selecting cases for staging in patients 
being considered for radical therapy as well as in selecting 
cases for re-staging after neoadjuvant treatment in patients 
being considered for radical therapy. It is further 
recommended in selecting cases to detect recurrence when 
other imaging is negative or equivocal and may be 
considered for routine follow-up of patients given the high 
incidence of recurrence. It may be considered for 
radiotherapy planning as several studies have shown a 
good correlation between FDG-PET and pathology-based 
tumor length [14]. PET is an important component in the 
staging algorithm for patients with cancers of the 
oesophagus and gastro-oesophageal junction. At some 
centers, it is employed early in the staging pathway with 
all patients being assessed by this modality. In other 
centers, it features later in the staging pathway, only being 
utilized if CT and endoscopic ultrasound demonstrate 
potentially resectable tumor characteristics [15-16]. 
DISCUSSION 
Accurate interpretation of PET/CT results in patients with 
OC, requires knowledge of the technical aspects of 
PET/CT image acquisition and the interpretative pitfalls 
that may be encountered. It also proves to be helpful, to 
understand how the disease manifests and disseminates, 
the staging criteria used, and the different management 
strategies available. The additional understanding of the 
role of metabolic parameters is also useful for the staging 
and prognosis of OC. 
 In the assessment of PET/CT scans, in previous studies 
quantification was conducted using only the mean or 
maximum Standard uptake value (SUVmax) of the 
primary tumor to evaluate disease status and prognosis. In 
considering the importance of whole-body tumor volume, 
a study performed with FDG PET determined that total 
metabolic tumour volume (MTV) was predictive of disease 
progression and obtained promising results [17]. 
 Tumor lesion glycolysis (TLG) is the product of mean 
of SUV and MTV and was first introduced by Larson et al 
to evaluate therapeutic response. It combines the 
volumetric and metabolic information of FDG PET. 
Studies have shown the usefulness of TLG for evaluating 
treatment response in different tumors. Recent studies 
further demonstrated the predictive value of pretreatment 
of TLG in osteosarcoma, malignant mesothelioma, and 
nasopharyngeal cancer. The prognostic value of TLG in 
OC is unknown. 
 For the most accurate evaluation of prognosis, both 
tumor activity and tumor volume over the whole body 
should be considered. The summation of whole-body 
tumor glycolysis, embodied by whole-body tumor lesion 
glycolysis TLG may represent tumor burden and may be a 
good indicator of prognosis. TNM stage is primarily based 
on the tumor anatomic site and size, whereas whole-body 
TLG has the advantage that it reflects both the biologic 
information, such as biologic aggressiveness and whole-
body total tumor volume.   
 The prognostic value of SUVmax in OC is unreliable 
in isolation. TLG is an independent prognostic factor for 
OC and is also a better predictor of survival than MTV and 
SUV in patients with locally advanced OC treated with 
radiotherapy [18-20]. The differences in SUV, MTV, and 
TLG between tumor histologies have not yet been 
investigated in OC. In lung cancer, the SUV of tumors 
with squamous cell histology are higher than that of 
adenocarcinomas. Differences in the SUV do not always 
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equate to differences in MTV and TLG. The differences in 
tumor histology may affect the different prognostic roles 
of MTV and TLG. Further large-scaled population-based 
analyses are warranted, including on the effect of tumor 
histology on metabolic parameters in OC [21].  
 Studies have found significant correlation between 
metabolic parameters and T stage in SUVmax in patients 
with initially diagnosed oesophageal squamous cell 
carcinoma (OSCC). T stage of the American Joint 
Committee on Cancer / Union for International Cancer 
Control’s (AJCC/UICC) classification system describes 
the depth of invasion, whereas SUVmax has been 
associated with histological and immune histochemical 
markers of aggressiveness [22-24].  
HIV & CA OESOPHAGOUS  
Immunosuppressed people, such as people with HIV 
infection, have an increased risk of developing cancer 
compared with the general population. Among people with 
HIV, some of these cancers are directly associated with 
immunosuppression, the high prevalence of coinfections, 
and increased prevalence of other risk factors, such as 
tobacco smoking [25-26]. Whereas some studies have 
reported increased risks of oesophageal and stomach 
cancers in HIV-infected people, other studies have 
reported no associations [27-29]. The risks of these 
cancers, while elevated, are likely not high enough to 
justify cost-effective screening of the overall HIV 
population [30]. Utilizing imaging modalities such as FDG 
PET/CT as staging tools may provide additional clinical 
diagnostic and prognostic information that will redirect or 
alter treatment.  
CONCLUSION 
It is clear that PET/CT is a validated diagnostic tool in 
staging of OC. The value of TLG in prognosis has been 
demonstrated in various solid tumours. With the high 
incidence of HIV in KZN, the association with oesophagus 
ca in this population may further compound the prognosis 
of OC. Thus, the use of TLG in HIV OC patients may 
assist in more accurate prediction of outcome and should 
be further investigated.    
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